Facebook
Twitter
LinkedIn
Forward
A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life
Program Introduction
A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.
Learning Objective
After completing this educational activity, you should be able to:
- Use expert-guided treatment strategies for patients with Duchenne muscular dystrophy.
Target Audience
Neurologists, NPs & PAs in neurology settings, and other treaters of DMD
Program Description
Join pediatric neurologist Dr. Aravindhan Veerapandiyan (Dr. Panda) from the Arkansas Children’s Hospital for an overview of best practices in the management of Duchenne muscular dystrophy. Through this presentation, viewers can gain a greater understanding of DMD pathophysiology, identify key signs suggestive of a diagnosis, and describe the benefits and limitations associated with the current standard of care. In the second half of this presentation, Dr. Veerapandiyan examines emerging therapeutic strategies poised to transform the management of Duchenne muscular dystrophy, which in recent years has transformed from a uniformly fatal pediatric disease into a more manageable, chronic condition. Interspersed throughout this video is the perspective of Amanda – a mother and caregiver of a child who lives with DMD. With this added voice, viewers can better appreciate the challenges faced by children with DMD and the need for coordinated, multidisciplinary care to optimize patient outcomes.
Support Statement
Supported by an educational grant from Sarepta Therapeutics,Inc.
Learning Objective
After completing this educational activity, you should be able to:
- Use expert-guided treatment strategies for patients with Duchenne muscular dystrophy.
Release, Review, and Expiration Dates
This CME activity was published in June 2023 and is eligible for AMA PRA Category 1 Credit™ through June 30, 2024.
Statement of Need and Purpose
One treatment goal for people with Duchenne muscular dystrophy (DMD) is maintenance of current functioning and quality of life (QoL). Ambulation loss is one of the most common issues for patients with DMD, and mobility impairment negatively affects daily life. While there is no cure, the development of new maintenance therapies can help improve the function, QoL, and longevity of patients with DMD. Clinicians often vary widely in their application of recommended standards of care. With an expanded treatment armamentarium, clinicians need education on therapies for maintenance in patients with DMD.
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter
© Copyright 2023 Physicians Postgraduate Press, Inc.
Faculty Affiliation
Aravindhan Veerapandiyan, MD |
|
Financial Disclosure
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Aravindhan Veerapandiyan, M.D., is a consultant for Biogen, Novartis, AveXis, Sarepta Therapeutics, PTC Therapeutics, Scholar Rock, Fibrogen, AMO pharma, Pfizer, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and France Foundation. He has received grant and research funding from Pfizer, Sarepta, RegenxBio, PPMD, MDA, AMO, Teva, Lilly, Edgewise, Capricor and Octapharma.
Bassam A. Bassam, M.D., FAAN
Professor of Neurology
University of South Alabama
Mobile, Alabama
Bassam A. Bassam, M.D., has received speaker honoraria from Argenx SE.
Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey
Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation